Intelligent Bio Solutions (Intelligent Bio Solutions) Interest Expense : $-0.17 Mil (TTM As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Intelligent Bio Solutions Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Intelligent Bio Solutions's interest expense for the three months ended in Mar. 2024 was $ -0.04 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.17 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Intelligent Bio Solutions's Operating Income for the three months ended in Mar. 2024 was $ -2.95 Mil. Intelligent Bio Solutions's Interest Expense for the three months ended in Mar. 2024 was $ -0.04 Mil. Intelligent Bio Solutions did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Intelligent Bio Solutions Interest Expense Historical Data

The historical data trend for Intelligent Bio Solutions's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Intelligent Bio Solutions Interest Expense Chart

Intelligent Bio Solutions Annual Data

Trend

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Interest Expense

Get a 7-Day Free Trial

-0.67

-0.46

-1.09

-0.01

-0.22

Intelligent Bio Solutions Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Interest Expense	Get a 7-Day Free Trial															-0.09	-0.06	-0.04	-0.03	-0.04

Intelligent Bio Solutions Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.17 Mil.

Intelligent Bio Solutions (NAS:INBS) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Intelligent Bio Solutions's Interest Expense for the three months ended in Mar. 2024 was $-0.04 Mil. Its Operating Income for the three months ended in Mar. 2024 was $-2.95 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2024 was $0.31 Mil.

Intelligent Bio Solutions's Interest Coverage for the quarter that ended in Mar. 2024 is calculated as

Intelligent Bio Solutions did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

Intelligent Bio Solutions (Intelligent Bio Solutions) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Intelligent Bio Solutions Inc (NAS:INBS) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

12Q:Germany

Address

57th Street, 142 West, 11th Floor, New York, NY, USA, 10019

Website

https://www.gbs.inc

Intelligent Bio Solutions Inc is a life sciences company developing non-invasive, real-time monitoring and diagnostic tests for patients and their primary health practitioners. Its Biosensor Platform is developing and launching diagnostic tests urgently needed to help people living with chronic diseases. It also engages in the advancement of portable drug abuse testing through the analysis of fingerprint sweat. The test is non-invasive, hygienic, and fast, and screens for recent use of opioids, cocaine, methamphetamines, benzodiazepines, and marijuana.

Executives

Harry Simeonidis	director, officer: CEO, President	708 THIRD AVENUE, 6TH FLOOR, NEW YORK CITY NY 10017
Foundation Ma-ran	10 percent owner	1908 CLIFF VALLEY WAY NE, ATLANTA GA 30329
Gary W. Rollins Foundation	10 percent owner	1908 CLIFF VALLEY WAY NE, ATLANTA GA 30329
David A Jenkins	director	P.O. BOX 682838, PARK CITY UT 84068
Jason Isenberg	director	1908 CLIFF VALLEY WAY NE, ATLANTA GA 30329
Spiro Kevin Sakiris	officer: Chief Financial Officer	708 THIRD AVENUE, 6TH FLOOR, NEW YORK CITY NY 10017
Life Science Biosensor Diagnostics Pty Ltd	10 percent owner	LEVEL 9, 85 CASTLEREAGH STREET, SYDNEY C3 2000
Tom Parmakellis	director	708 THIRD AVENUE, 6TH FLOOR, NEW YORK CITY NY 10017
Victoria Gavrilenko	director	708 THIRD AVENUE,, 6TH FLOOR, NEW YORK CITY NY 10017
Christopher Towers	director	1981 MARCUS AVENUE, SUITE 130, LAKE SUCCESS NY 11042
Lawrence B Fisher	director	C/0 FINANCIAL FEDERAL CORP, 733 THIRD AVENUE, NEW YORK NY 10017
Leonard Victor Kempler	director	708 THIRD AVENUE,, 6TH FLOOR, NEW YORK CITY NY 10017
George Margelis	director	708 THIRD AVENUE, 6TH FLOOR, NEW YORK CITY NY 10017
Boyages Steven Constantine	director	708 THIRD AVENUE,, 6TH FLOOR, NEW YORK CITY NY 10017
Jonathan Scott Hurd	director	708 THIRD AVENUE,, 6TH FLOOR, NEW YORK CITY NY 10017